CEL-SCI Corporation (NYSE American: CVM) has closed its best-efforts public offering of 6 million shares of common stock at $1.20 per share, generating gross proceeds of approximately $7.2 million before deducting fees and expenses. The company announced the closing on [date], stating that net proceeds will be used to support the continued development of Multikine, its investigational immunotherapy for head and neck cancer, as well as for general corporate purposes and working capital.
Multikine (Leukocyte Interleukin, Injection) is designed to boost a patient's immune system before surgery, radiotherapy, and chemotherapy have damaged it, potentially providing the greatest impact on survival. The therapy aims to help the immune system target the tumor at a time when the immune system is still relatively intact, thereby mounting a more effective attack. Multikine has been dosed in over 740 patients and has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck.
The successful closing of this offering provides CEL-SCI with additional capital to advance its clinical programs. According to the press release, the company plans to use the funds to further develop Multikine, which represents a potential new treatment approach for a patient population with significant unmet medical need. Head and neck cancer remains a challenging disease, and new therapies that can improve outcomes are eagerly awaited.
For more details on the offering, the full press release is available at https://ibn.fm/T5Ng2. Additional information about CEL-SCI and its operations can be found on the company's website at https://cel-sci.com/.
The offering was conducted on a best-efforts basis, meaning the underwriters were not obligated to purchase any unsold shares. The company's ability to close the offering reflects investor confidence in its pipeline and the potential of Multikine. With the additional funds, CEL-SCI is well-positioned to continue its research and development efforts, moving closer to potential regulatory submissions and commercialization.
Investors and industry observers will be watching for updates on Multikine's clinical progress, as positive results could significantly impact the treatment landscape for head and neck cancer. The company's focus on neoadjuvant therapy—treatment given before primary therapy—is a unique approach that could differentiate Multikine from other immunotherapies.
